Targeting pancreatic ductal adenocarcinoma: New therapeutic options for the ongoing battle

Hepatobiliary Pancreat Dis Int. 2022 Feb;21(1):4-6. doi: 10.1016/j.hbpd.2021.09.004. Epub 2021 Sep 7.

Authors

Pratibha Malhotra¹, Ranjith Palanisamy¹, Marco Falasca²

Affiliations

¹ Metabolic Signalling Group, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, 6102, Australia.
² Metabolic Signalling Group, Curtin Medical School, Curtin Health Innovation Research Institute, Curtin University, Perth, WA, 6102, Australia. Electronic address: marco.falasca@curtin.edu.au.

PMID: 34535394
DOI: 10.1016/j.hbpd.2021.09.004

No abstract available

Publication types

Editorial

MeSH terms

Carcinoma, Pancreatic Ductal* / drug therapy
Drug Delivery Systems* / methods
Humans
Pancreatic Neoplasms* / drug therapy